Henry Schein (HSIC) Lowered to “Strong Sell” at ValuEngine

ValuEngine lowered shares of Henry Schein (NASDAQ:HSIC) from a sell rating to a strong sell rating in a research report sent to investors on Sunday morning.

A number of other equities research analysts have also weighed in on the stock. BidaskClub raised shares of Henry Schein from a sell rating to a hold rating in a report on Thursday. Zacks Investment Research downgraded shares of Henry Schein from a hold rating to a sell rating in a research report on Wednesday, February 6th. UBS Group initiated coverage on shares of Henry Schein in a research report on Thursday, January 17th. They issued a sell rating and a $73.00 price target on the stock. Evercore ISI downgraded shares of Henry Schein from an in-line rating to an underperform rating and set a $76.39 price target on the stock. in a research report on Thursday, January 3rd. Finally, Robert W. Baird downgraded shares of Henry Schein from an outperform rating to a neutral rating and set a $76.60 price target on the stock. in a research report on Wednesday, January 2nd. Six investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $84.19.

HSIC opened at $59.15 on Friday. Henry Schein has a fifty-two week low of $57.78 and a fifty-two week high of $91.35. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.70 and a current ratio of 1.30. The company has a market cap of $9.02 billion, a price-to-earnings ratio of 16.43, a price-to-earnings-growth ratio of 1.86 and a beta of 0.89.



Henry Schein declared that its board has initiated a share buyback plan on Thursday, December 13th that authorizes the company to buyback $400.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 3.1% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

In related news, CEO Stanley M. Bergman sold 69,000 shares of the business’s stock in a transaction on Friday, December 7th. The shares were sold at an average price of $86.32, for a total transaction of $5,956,080.00. Following the transaction, the chief executive officer now owns 240,096 shares in the company, valued at approximately $20,725,086.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Steven Paladino sold 21,110 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $90.06, for a total transaction of $1,901,166.60. The disclosure for this sale can be found here. Insiders have sold a total of 105,856 shares of company stock worth $9,222,275 in the last quarter. 1.15% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. ETRADE Capital Management LLC acquired a new position in shares of Henry Schein during the 4th quarter valued at $556,000. AGF Investments Inc. acquired a new position in Henry Schein during the fourth quarter worth $196,000. Massachusetts Financial Services Co. MA raised its holdings in Henry Schein by 112.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 295,605 shares of the company’s stock worth $23,211,000 after buying an additional 156,279 shares during the last quarter. Centerstone Investors LLC acquired a new position in Henry Schein during the fourth quarter worth $7,482,000. Finally, BlackRock Inc. raised its holdings in Henry Schein by 4.6% during the fourth quarter. BlackRock Inc. now owns 11,118,102 shares of the company’s stock worth $872,993,000 after buying an additional 488,210 shares during the last quarter.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Recommended Story: What is net income?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply